AcelRx pain treatment as effective as standard care in late-stage trial
Post surgical pain treatment
AcelRx Pharmaceuticals Inc said its treatment for post-operative pain was at least as effective as the standard of care, according to initial data from a late-stage study.
The open-label study tested the company's ARX-01 Sufentanil NanoTab patient-controlled analgesia (PCA) system against intravenous PCA with morphine on 359 adult patients.
"Nurses managing patients in the study and the patients themselves reported that they had significantly greater overall satisfaction with the NanoTab System compared to intravenous PCA morphine," the company said in a statement.
Patient-controlled systems are typically used to administer pain medication to patients after surgery, allowing them to alter the dosage depending on the level of relief they need.
Morphine is one of the most common drugs used in such systems, but it comes with side-effects such as nausea, vomiting and even addiction.
AcelRx said its NanoTab device, which consists of a handheld system, provides a more mobile way of treating pain while reducing the side-effects that come with drugs such as morphine.
Studies report that about 75 percent of patients experience inadequate pain relief after surgery, despite using analgesics, according to AcelRx's website.